DUBLIN--(BUSINESS WIRE)--The "The Global Genetic Testing Market by Hereditary, Newborn, NIPT, Oncology, Pharmacogenomic and Direct to Consumer, With Executive and Consultant Guides 2020 to 2024" report has been added to ResearchAndMarkets.com's offering.
This report forecasts the market size out to 2024. The report includes detailed breakouts for 14 countries and 5 regions.
Will all newborns receive Whole Genomic Sequencing at birth? What key interest is driving Direct to Consumer?
The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower pricing is driving the Genetic Testing industry to record growth. New drugs may only work for people with a certain genetic makeup, and this too is driving the Genetic Testing Industry. The traditional genetic testing market is growing in volume and growing in the breadth of tests creating a new life for the industry.
Predictive Diagnostics? Pharmacogenomic Testing? Direct to Consumer? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find opportunities and pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
All report data is available in Excel format on request
Key Topics Covered
1. Introduction and Market Definition
1.1 Genetic Testing Definition in This Report
1.2 The Genomics Revolution
1.3 Market Definition
1.3.1 Revenue Market Size
1.4 U.S. Medical Market and laboratory Testing - Perspective
1.4.1 U.S. Medicare Expenditures for Laboratory Testing
2. Market Overview
2.1 Market Participants Play Different Roles
2.1.1 Supplier/pharmaceutical
2.1.2 Independent lab specialized/esoteric
2.1.3 Independent lab national/regional
2.1.4 Independent lab analytical
2.1.5 Public National/regional lab
2.1.6 Hospital lab
2.1.7 Physician lab
2.1.8 DTC Lab
2.1.9 Independent Genetic Testing Lab
2.1.10 Audit Body
2.2 Genetic Tests -Types, Examples and Discussion
2.2.1 Preimplantation Genetic Diagnosis- An Emerging Market
2.2.2 Prenatal Diagnosis - New Technologies Create Opportunity
2.2.3 Newborn Screening
2.2.2 Diagnostic Testing
2.2.3 Carrier Testing
2.2.6 Predictive and Presymptomatic Testing
2.2.7 Pharmacogenomics
2.2.8 Forensic Testing
2.2.9 Parental Testing
2.2.10 Ancestral Testing
2.3 Industry Structure
2.3.1 Hospital's Testing Share
2.3.2 Economies of Scale
2.3.2.1 Hospital vs. Central Lab
2.3.3 Physician Office Lab's
2.3.4 Physician's and POCT
2.4 Market Shares of Key Genetics Players - Analysis
3. Market Trends
3.1 Factors Driving Growth
3.1.1 Genetic Discoveries Creating New Diagnostic Markets
3.1.2 Aging Population a Boon for Diagnostics
3.1.3 Pharmacogenomics Drives Further Growth
3.1.4 Oncology and Liquid Biopsy Enter New Era
3.1.5 Fertility Practice Growth drives market
3.1.6 Direct to Consumer begins to break out
3.2 Factors Limiting Growth
3.2.1 Increased Competition Lowers Price
3.2.2 Lower Costs
3.2.3 Testing usage analysis curtailing growth
3.2.4 Wellness has a downside
3.3 Instrumentation and Automation
3.3.1 Instruments Key to Market Share
3.3.2 Bioinformatics Plays a Role
3.4 Diagnostic Technology Development
3.4.1 Next Generation Sequencing Fuels a Revolution
3.4.2 Impact of NGS on pricing
3.4.3 POCT/Self Testing Disruptive Force
3.4.4 Pharmacogenomics Blurs Diagnosis and Treatment
3.4.5 CGES Testing, A Brave New World
3.4.6 Biochips/Giant magnetoresistance based assay
4. Genetic Testing Recent Developments
4.1.1 Importance of This Section
4.1.2 How to Use This Section
- Blueprint Genetics, Archimedlife to Launch Genetic Testing in North America
- Invitae to Offer No-Charge Genetic Testing to Pancreatic Cancer Patients
- Phosphorus Offers DNA Testing to Assess Disease Risk
- Arivale Shuts Down Personalized Wellness Business
- ArcherDX Acquires Baby Genes
- MDxHealth, LifeLabs Ink Distribution Agreement for Prostate Cancer Assay
- Thermo Fisher Purchases 9 Percent Stake in Yourgene Health
- Invitae Partners to Expand Free Epilepsy Genetic Testing Program
- Illumina, Chinese Firm Partner on NGS System for Genetic Disease Dx
- NanoString Technologies Prices $103.5M Common Stock Offering
- Canine Consumer Genomics Firm Embark Veterinary Raises $10M
- Yourgene Health to Acquire Elucigene
- Helix, AdventHealth Partner on Genetic Screening Study
- Qiagen, NeuMoDx Ink Partnership, Merger Agreement
- Prenetics Acquires DNAFit for $10M
- Myriad Genetics to Acquire Counsyl for $375M
- Roche inks $2.4B deal to buy out Foundation Medicine
- Rapid genome sequencing could revolutionize health care
- Scientists discover new nanoparticle, dubbed exomeres, released by tumours
- New DNA tests look for 190 diseases in newborn's genetic code
- Cordlife, PlumCare Partner to Offer Genetic Testing Services in Asia
- New genetic risk score could help guide screening decisions for prostate cancer
- Tele-genetics pilot makes genetic counselling accessible
- Digital Genetic Assistant OptraGURU Launches Today from Optra Health
- PacBridge Capital Partners Invests C$12M in Contextual Genomics
- From DNA To Disease: A Diagnosis Made In Under A Day
5. Profiles of Key Companies
- 10x Genomics, Inc
- 23andME Inc
- Abbott Diagnostics
- AccuraGen Inc
- Adaptive Biotechnologies
- Admera Health, LLC
- Agena Bioscience, Inc
- Agilent
- Akonni Biosystems
- Ancestry.com LLC
- Anchor Dx
- ArcherDx, Inc
- ARUP Laboratories
- Asuragen
- Baylor Miraca Genetics Laboratories
- Beckman Coulter, Inc
- Becton, Dickinson and Company
- BGI Genomics Co. Ltd
- Bioarray Genetics
- Biocept, Inc
- Biodesix Inc
- BioFluidica
- BioGenex
- Biolidics Ltd
- bioMerieux Diagnostics
- Bioneer Corporation
- Bio-Rad Laboratories, Inc
- Bio-Techne
- Cancer Genetics
- Caris Molecular Diagnostics
- CellMax Life
- Centogene
- Chronix Biomedical
- Circulogene
- Clinical Genomics
- Color Genomics
- Complete Genomics, Inc. - A BGI Company
- Cynvenio
- Dante Labs
- Datar Cancer Genetics Limited
- Diasorin S.p.A
- Epic Sciences
- Epigenomics AG
- Eurofins Scientific
- Excellerate Bioscience
- Exosome Diagnostics
- Fabric Genomics
- Fluidigm Corp
- Foundation Medicine
- Freenome
- FUJIFILM Wako Diagnostics
- Fujirebio
- GE Global Research
- GE Healthcare Life Sciences
- Gene by Gene, Ltd
- Genedrive
- GeneFirst Ltd
- Genetron Health (Beijing) Co., Ltd
- Genewiz
- Genomic Health
- Genomics England
- Genomics Personalized Health (GPH)
- GenomOncology
- Genzyme Corporation
- Grail, Inc
- Grifols
- Guardant Health
- Guardiome
- HeiScreen
- Helix
- Helomics
- Hologic
- Horizon Discovery
- HTG Molecular Diagnostics
- Human Longevity, Inc
- iCellate
- Illumina
- Incell Dx
- Inivata
- Integrated Diagnostics
- Invitae Corporation
- Invivoscribe
- Karius
- Macrogen
- MDNA Life SCIENCES, Inc
- MDx Health
- Medgenome
- Meridian Bioscience
- Mesa Biotech
- MIODx
- miR Scientific
- MNG Labs
- Molecular MD
- NantHealth, Inc
- Natera
- Nebula Genomics
- NeoGenomics
- New Oncology
- Novogene Bioinformatics Technology Co., Ltd.
- Omega Bioservices
- OncoDNA
- ORIG3N, Inc
- Origene Technologies
- Oxford Nanopore Technologies
- Pacific Biosciences
- Panagene
- Perkin Elmer
- Personal Genome Diagnostics
- Personalis
- Precipio
- PrecisionMed
- Promega
- Protagen Diagnostics
- Qiagen Gmbh
- Quantumdx
- Regeneron
- Roche Molecular Diagnostics
- Roswell Biotechnologies
- Seegene
- Sequencing.com
- Siemens Healthineers
- simfo GmbH
- Singlera Genomics Inc
- SkylineDx
- Stratos Genomics
- Sure Genomics, Inc
- Sysmex
- Sysmex Inostics
- Tempus Labs, Inc
- Thermo Fisher Scientific Inc
- Veritas Genetics
- Volition
6. Global Market Size
6.1 Global Market by Country
6.2 Global Market by Application
7. Market Sizes by Application
7.1 Hereditary Testing Market
7.2 Newborn Testing Market
7.3 NIPT Testing Market
7.4 Oncology Testing Market
7.5 Pharmacogenomic Testing Market
7.6 Direct to Consumer Testing Market
8. The Future of Genetic Testing
For more information about this report visit https://www.researchandmarkets.com/r/2llelf
